Sarepta Therapeutics Gross Profit

The latest gross profit for SRPT is $520M as of June 2026. That compares with $2.1B in the prior-year period — down 75.0% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Sarepta Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SRPT's gross profit moved from $2.1B to $520M — a 75.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sarepta Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, SRPT currently prints $520M for gross profit, while the sector average sits near $65B. That is roughly 99.2% below the sector mean. Large gaps often invite a closer look at Sarepta Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $520M for SRPT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting SRPT's gross profit ($520M), review year-over-year change from $2.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.